CanaQuest Medical Corp is engaged in the development of proprietary research and products utilizing cannabis oil combined with other botanical and nutraceutical extracts, including algae oil. Positive data from our research and pre-clinical trials has demonstrated that our strategy is achieving meaningful results. The company has engaged two prestigious Canadian universities, Western University and the University of Waterloo, to provide research, and to create these formulations and products, where research is focused on the development of our novel pharmacotherapies for mental health and mitigation of the spread of cancerous tumors respectively.

CanaQuest’s strategy includes the continuous development of our Master Intellectual Property Platform of patented product formulations. CanaQuest is also in the process of obtaining a purchase/sale, import/export license for cannabis and cannabis products as permitted under the Health Canada Cannabis Act.


Working in partnership with Professor Kirsten Mueller, head of the Biology Department and the Canadian Phycology (the study of algae) Lab at the University of Waterloo for five years, we have gained extensive experience with production, extraction and health benefits of Omega-3 derived from algae.

In 2016, we extended our research to examine extraction technologies and the health benefits of cannabis oils as well as the synergy between cannabis oils and Omega-3 oils. Resent studies have shown strong evidence that essential fatty acids found in Omega-3 improve the functionality of the CB1 and CB2 receptors in the human body’s endocannabinoid system, thus enhancing the effectiveness of cannabis treatments.


Our vision is to be a global leader in the formulation and development of health products from cannabis derivatives.


Utilizing university-level research we have created specific cannabis oil lines.

Western University has performed research and product development on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety, and schizophrenia.

Dr. Steven Laviolette, BSc, PhD
Addiction Research Group
Dept. of Anatomy & Cell Biology. Dept. of Psychiatry
Canadian Institute for Military and Veterans Health Research

A research team at Western University in London, Ontario, led by Dr Steven Laviolette of the Department of Anatomy and Cell Biology, and the Department of Psychiatry, is examining cannabis oil and its constituents in the context of anxiety, depression, schizophrenia and post-traumatic stress disorder (PTSD).  With over 12 years of related research behind it, Laviolette’s team is excited by the promise of the new formulations they’re developing. Clinical trial data using animal subjects has shown positive results.

“The clinical implications and commercial potential are highly significant,” Laviolette said. “Furthermore, since cannabis is commonly prescribed for a host of ailments, including pain, nausea, glaucoma, multiple sclerosis, osteoarthritis, our formulation will again be hugely significant for the non-mental health patient sectors as well.”

CanaQuest is now initiating human feasibility trials with an independent, third-party organization, which will be followed by human trial programs with two recognized clinics based on the successful results from the research, animal preclinical data from the lab, Western University and the human feasibility trial results. The first trial will focus on mental health (anxiety, depression) and the second will focus on pain management as an alternative to opioids.

In addition, the researchers at the University of Waterloo are exploring other areas that have shown positive results for the use of cannabis including:

  • Colorectum, pancreas, breast and prostate cancer;
  • Ongoing R & D – mitigation of the spread of cancerous tumors; and
  • Combined application of natural botanicals, algae essential fatty acids, and cannabis oils.
Dr. Steven Laviolette

The University of Waterloo has performed research and product development on cannabis oil and its constituents in the context of development and treatment of cancers of the colorectum, pancreas, breast and prostate.

Dr. Jonathan Blay, PhD, FRSB, FIBMS, Csci, Cbiol
Professor of Pharmacy, University of Waterloo
Professor of Pathology, Dalhousie University

CanaQuest’s second sponsored research project, with the University of Waterloo in the Ontario city of the same name, focuses on cannabis oil and its constituents for the supportive treatment of cancers, particularly those of the large bowel (colon), breast and prostate.  This research team is led by Dr Jonathan Blay, an oncologist and professor of pharmacy at the University of Waterloo and a leading expert whose 30-year career has resulted in the discovery of several novel anti-cancer approaches and their clinical application.

Working within his state-of-the-art cancer research laboratory, Blay and his team are developing cannabis-based formulations to enhance the efficacy of cancer treatments. The six-member team has skills and experience extending from molecular biology through to clinical research. Their focus is not upon direct killing of the cancer cells but on modulating cellular behavior so as to reduce the capacity of cells to form aggressive disease and/or spread throughout the patient (metastasis). Their cutting-edge work using preclinical models have identified formulations that have the potential to change cellular properties that contribute to the progression of cancer. CanaQuest is now moving to apply this work to veterinary and human trials and to determining the best oral delivery approach.

Dr. Jonathan Blay

CanaQuest Medical Corp will retain the rights of all patents developed in collaboration with universities.